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When you search PubMed for ‘EGF receptor’ (EGFR), the
database returns more than 5000 hits. This is not entirely
surprising given the receptor’s eminent role in cancer biology.
However,itistrulysurprisingthattworecentpaperspublished
by the groups of Gavin MacBeath and Matthias Mann add
a whole new dimension to the problem of EGFR signaling.
They do that by using protein microarray and quantitative
proteomics technologies to comprehensively and quantita-
tively identify proteins associated with the cytosolic domains
of the human EGFR family (Jones et al, 2005; Schulze et al,
2005).
This family of membrane receptors consists of four different
proteins called EGFR/ErbB1/HER1, ErbB2/Neu/HER2, ErbB3/
HER3, and ErbB4/HER4. Under normal physiological condi-
tions, the ErbB receptors play crucial roles in propagating
signals regulating cell proliferation, differentiation, motility,
andapoptosis(HolbroandHynes,2004).Theyareactivatedby
ligand binding, which leads to homo- or heterodimerization
followed by trans-phosphorylation of speciﬁc tyrosine resi-
dues. These phosphorylated tyrosines, in turn, provide
recognition sites for cytoplasmic proteins, which link ErbB
receptorsto downstreamsignaling transduction cascades such
as the MAP kinase pathway. Among all ErbB family members,
EGFRand ErbB4 are fully functional receptor tyrosine kinases,
whereas ErbB2 does not bind any known ligand and ErbB3
has no intrinsic kinase activity (however, they still affect
the activity of their partners by heterodimerization). As
overexpression of EGFR and ErbB2 receptors is often found
in several human tumors such as breast, lung, head, and
neck (Marmor et al, 2004), their precise role in the cell is of
particular biological and pharmacological importance.
In the ﬁrst large-scale ErbB-interactome study, Schulze et al
(2005) used a quantitative proteomic approach for identifying
proteins associated with phosphotyrosine motifs of the ErbB-
receptor members. To this end, they generated 89 different
‘bait’peptidesinphosphorylatedandunphosphorylatedforms
covering all intracellular tyrosine residues of the ErbB-family
members. In the next step, these peptides bearing phosphory-
lated and unphosphorylated tyrosine residues were incubated
with HeLa cell lysates and pulldown experiments were
performed to enrich speciﬁc binding partners for the phos-
phorylated bait peptides. Lastly, these proteins were identiﬁed
andquantiﬁed bymass spectrometry.Surprisingly,only 40out
of the 89 examined tyrosine residues did have an interacting
protein in their phosphorylated form. Most of the tyrosine
residues that interacted with speciﬁc partners accumulated at
the C-terminal regions of the receptors. This study also
indicated that the distribution of interacting partners of
the different ErbB members shows clear differences between
individual receptors, but also a signiﬁcant overlap. For
example, both EGFR and ErbB4 have multiple binding sites
fortheadaptorproteinsShcandGrb2,butonlyEGFRbindsthe
ubiquitin ligase Cbl, whereas ErbB4 is unique in binding Nck.
Altogether,Schulzeetalfound10ErbBinteractors,allofwhich
have either an SH2 or PTB domain, thus emphasizing the
speciﬁcity of these signal transduction modules (Pawson and
Nash, 2003).
In a related project, Jones et al used protein microarrays
to identify ErbB interactors. Since the phosphotyrosines in
ErbB receptors are primarily bound by SH2 and PTB domains,
Jones et al successfully expressed and puriﬁed 106 (out of 109)
SH2 domains and 41 (out of 44) PTB domains encoded in
the human genome. These domains were then spotted
onto glass slides and subsequently probed with ErbB peptides
that contained phosphorylated and nonphosphorylated
tyrosines, respectively. While Schulze et al used all possible
89 tyrosine-containing ErbB peptides for their pulldowns,
Jones et al concentrated on 29 peptides that were known to
be phosphorylated in EGFR, ErbB2 and ErbB3, and four
peptides that were predicted to be phosphorylated in ErbB4.
These experiments revealed that each phosphotyrosine on
EGFRbindssevendifferentproteinsonaverage,whereasthose
on ErbB2, ErbB3 and ErbB4 bind 17, 9 and 2 proteins on
average, respectively. This adds up to many interactions,
namely 54 with EGFR, 59 with ErbB2, 37 with ErbB3 and 8
with ErbB4, most of which were new. The sobering fact is
that the mass spec study by Schulze et al found quite different,
and, in fact, much smaller numbers, namely nine, four,
four, and eight different interacting proteins for the four
receptors, respectively. While at least the number of identiﬁed
ErbB4 interactors by both approaches appears to be identical,
only one protein (Shc) is actually common to both ErbB4
data sets.
Where do these dramatic differences come from? Well,
simply from the fact that the two groups looked at very
different things: while Schulze et al pulled down proteins that
most likely bind to ErbB receptors in HeLa cells, Jones et al
looked at the whole SH2/PTB interaction space of ErbB
receptors in vitro. That is, Jones et al told us which SH2 and
PTB domains may bind towhich receptorif both arepresentin
a cell. In contrast, Schulze et al told us which SH2 and PTB
proteins bind to ErbB receptors speciﬁcally in HeLa cells.
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Article number: 2006.0006Unfortunately, we have to wait until further studies reveal
which proteins can be pulled down in the other 200þ human
cell types or, alternatively, which of the ErbB receptors and
SH2/PTB proteins are expressed together in those cells. At
least we know that the proteins detected in Schulze are
coexpressed in HeLa; some differences (e.g., Grb2 interacts
with all four ErbB in Schulze but only with ErbB2 in Jones;
STAT5 interaction is missed altogether in Jones) might also be
due to possible methodological differences. Actually, Jones
et al reminded us that the task will become even more
dauntingwhenthermodynamicaspectscomeintoplay.Infact,
the MacBeath group measured afﬁnity constants for all their
interactions too, but this is another story that will eventually
require data about in vivo concentrations of all those proteins
(in all human cell types!) for meaningful interpretation.
Systems biologists need exactly this kind of information after
all,andsome,suchasOdaetal(2005),mayarguethatsystems
biology only becomes feasible once we have this information
in computer-readable form. Never mind the 5000þ papers, at
the end of the day two papers were enough to convince us that
we are still at the beginning of systems biology!
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